In today’s rapidly evolving scientific landscape, eliminating barriers to progress is more critical than ever. Precision medicine and targeted therapies hold great promise but are dependent on the ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade ...

“The state of DNA synthesis is a bit like humanity’s journey to the moon—just because something has been achieved before doesn’t mean we should cease figuring out how to do it better.” That is how ...

There’s an old saying about a dollar waiting on a dime. In other words, a monumental endeavor may become stuck at some point if a key preliminary element remains unavailable. The saying could be ...

Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based ...

Fully automated SYNTAX platform features latest STX-200 system, enzymatic biochemistry advances, and ready-to-use reagents for producing up to 96 oligos that are up to 120 nt long in less than a day ...

Ansa Biotechnologies Secures $54.4 Million in Series B Financing to Redefine How Scientists Access Synthetic DNA with Industry’s First Guaranteed On-Time Service Funding enables company to scale its ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. DNA synthesis is vital to several processes in biopharmaceutical innovation, including the ...

The International Gene Synthesis Consortium (IGSC), an organization of the world’s leading gene synthesis companies, continues to drive the advancement of biosecurity screening. A recent “red teaming” ...

For the first time, chemists have fully synthesized verticillin A, a notoriously complex fungal molecule with striking anticancer potential.